10 Grants
1998
A Randomized, Double- Blind, Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Bactericidal/ Permeability- Increasing Protein (rBPI21) for Treatment of Patients with Hemorrhage due to Trauma- Phase III
Gomez, Gerardo A
Xoma Corporation, $480,000, 1998 -- 1999
1997
Pharmacokinetic/Dynamic Study in Patients with Severe Sepsis
Gomez, Gerardo A
Eli Lilly & Co., $60,000, 1997
1995
A Randomized, Double- blind, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Bactericidal/ Permeablity- Increasing Protein (rBPI21) for Treatment of Patients with Hemorrhage due to Trauma- PhaseII
Gomez, Gerardo A
Xoma Corporation, $205,000, 1995 -- 1997
 
National Acute Brain Injury Study: Hypothermia
Gomez, Gerardo A
National Institutes Of Health, $360,000, 1995 -- 1998
1993
A Randomized, Placebo- Controlled Trial of E5 Antiendotoxin Monoclonal Antibody in Patients with Severe Sepsis
Gomez, Gerardo A
Pfizer, Inc., Roerig Division, $35,750, 1993 -- 1997
 
Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center North American Study of the Safety and Efficacy of Murine Monoclonal Antibody to Tumor Necrosis Factor (TNF Mab) for the Treatment of Patients with Septic Shock
Gomez, Gerardo A
Bayer, $73,817, 1993 -- 1997
1987
A Prospective Comparison of Prophylactic Ticarcillin Disodium/ Clavulatnate Potassium and Cefoxitin in Penetrating Abdominal Trauma
Gomez, Gerardo A
Beecham Laboratories, $105,000, 1987
1984
A Comparative Study for the Evaluation of Noxalactam (BID) and Gentamicin Plus Clindamycin in the Treatment of Patients with Penetrating Abdominal Injuriesc
Gomez, Gerardo A
Eli Lilly And Co., $75,000, 1984
1983
The Evaluation of Aztreonam in the Treatment of Serious Gram- Negative Infections
Gomez, Gerardo A
Sqibb & Sons, Inc., $22,800, 1983
n.d.no date or unknown
Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center North American Study of the Sfety and Efficacy of Murine Monoclonal Antibody to Tumor Necrosis Factor (TNF Mab)
Gomez, Gerardo A
Bayer, unknown